Scarica l'app Stockscreener
10.32
5.80%
-0.635
Dopo l'orario di chiusura:
10.60
0.28
+2.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Precedente Chiudi:
$10.96
Aprire:
$10.86
Volume 24 ore:
41,746
Relative Volume:
0.72
Capitalizzazione di mercato:
$61.52M
Reddito:
$100.44M
Utile/perdita netta:
$-133.16M
Rapporto P/E:
-0.4006
EPS:
-25.76
Flusso di cassa netto:
$-94.85M
1 W Prestazione:
-8.83%
1M Prestazione:
+11.81%
6M Prestazione:
+22.57%
1 anno Prestazione:
+36.15%
Intervallo 1D:
$10.32
$11.45
Intervallo di 1 settimana:
$10.32
$11.84
Portata 52W:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Nome
Atara Biotherapeutics Inc
Settore
Industria
Telefono
805-623-4211
Indirizzo
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Confronta ATRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
10.32 | 67.87M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
638.90 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-20 | Downgrade | Citigroup | Neutral → Sell |
| 2022-07-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2021-05-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-30 | Iniziato | Evercore ISI | Outperform |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Downgrade | Goldman | Neutral → Sell |
| 2019-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2019-06-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-05-30 | Iniziato | ROTH Capital | Buy |
| 2019-05-23 | Iniziato | Stifel | Buy |
| 2019-01-23 | Iniziato | Mizuho | Buy |
| 2018-04-10 | Iniziato | JP Morgan | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2018-03-05 | Reiterato | Jefferies | Buy |
| 2018-02-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Downgrade | Citigroup | Neutral → Sell |
| 2018-01-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
Atara Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress | ATRA Stock News - GuruFocus
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress - Business Wire
How Atara Biotherapeutics Inc. stock performs during market volatilitySecure Asset Flow and Trend Pattern Analysis - Newser
Will Atara Biotherapeutics Inc. price bounce be sustainableCapital Safe Picks with Consistent Gains - Newser
Understanding Atara Biotherapeutics Inc.’s price movementAI Powered Buy Point Forecast Planner - Newser
How to interpret RSI for Atara Biotherapeutics Inc. stockLow Drawdown Picks with Weekly Updates - Newser
What MACD signals say about Atara Biotherapeutics Inc.High Return Idea With Technical Filter - Newser
How high can Atara Biotherapeutics Inc. stock goFree Alert Feed for Momentum Based Picks - Newser
Is Atara Biotherapeutics Inc. showing signs of accumulationBuy Strategy Tracker with Growth Indicators - Newser
Multi asset correlation models including Atara Biotherapeutics Inc.Free Real Time Stock Movement Analysis - Newser
Risk vs reward if holding onto Atara Biotherapeutics Inc.Daily Profit Watch With Forecast Confidence - Newser
Atara ATRA Q2 2025 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Risk adjusted return profile for Atara Biotherapeutics Inc. analyzedMarket Liquidity and Price Flow Analysis - Newser
Atara Biotherapeutics Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Biotech with Heart: Atara’s Path to Hope for MS & Cancer - Tomorrow's World Today
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Is About To Turn The Corner - sg.finance.yahoo.com
What is Atara Biotherapeutics Inc. company’s growth strategyUnlock powerful portfolio management tools - Jammu Links News
What is the risk reward ratio of investing in Atara Biotherapeutics Inc. stockUnlock exclusive trading strategies for gains - Jammu Links News
What are analysts’ price targets for Atara Biotherapeutics Inc. in the next 12 monthsStrong return on investment - Jammu Links News
What are the latest earnings results for Atara Biotherapeutics Inc.Rapid wealth multiplication - Jammu Links News
Does Atara Biotherapeutics Inc. stock perform well during market downturnsHigh-yield trading alerts - Jammu Links News
When is Atara Biotherapeutics Inc. stock expected to show significant growthUnlock powerful portfolio optimization tools - Jammu Links News
What analysts say about Atara Biotherapeutics Inc. stockDiscover stocks with explosive upside potential - Jammu Links News
Should I hold or sell Atara Biotherapeutics Inc. stock in 2025Maximize profits with strategic stock selection - Jammu Links News
What institutional investors are buying Atara Biotherapeutics Inc. stockTriple-digit wealth increases - Jammu Links News
What are Atara Biotherapeutics Inc. company’s key revenue driversGet real-time alerts on top-performing stocks - Jammu Links News
What drives Atara Biotherapeutics Inc. stock priceUnlock daily market insights for better trades - Jammu Links News
What is the dividend policy of Atara Biotherapeutics Inc. stockMaximize returns with disciplined trading approaches - Jammu Links News
What catalysts could drive Atara Biotherapeutics Inc. stock higher in 2025Discover high-growth stocks for your portfolio - Jammu Links News
Why is Atara Biotherapeutics Inc. stock attracting strong analyst attentionInvest smarter with data-backed trading alerts - Jammu Links News
Is it the right time to buy Atara Biotherapeutics Inc. stockConsistent high-yield stocks - Jammu Links News
What makes Atara Biotherapeutics Inc. stock price move sharplyNavigate market shifts with confidence - Jammu Links News
FDA Accepts Atara Biotherapeutics’ Resubmission of BLA for Tabelecleucel - CGTLive®
Atara Biotherapeutics Plunges 16.09% Post Reverse Split - AInvest
Atara Biotherapeutics Inc. Stock Lags Behind Sector BenchmarksHigh Accuracy Alerts for ROI Traders Detected - metal.it
Atara Biotherapeutics Inc. Recovery Potential Based on Technical ToolsValue Investing Picks With Stability Outlined - metal.it
Published on: 2025-07-29 09:26:28 - metal.it
Fibonacci Support Holding Strong in Atara Biotherapeutics Inc.Multi-Bagger Potential Stock Forecast Tools Released - metal.it
Published on: 2025-07-28 23:04:32 - metal.it
Is Atara Biotherapeutics Inc. a growth stock or a value stockRapid return acceleration - Jammu Links News
Intrinsic Value of Atara Biotherapeutics Inc. Stock: Is It Undervalued or Overvalued Portfolio Positioning Strategy With Timing - metal.it
What are the technical indicators suggesting about Atara Biotherapeutics Inc.Build wealth faster with disciplined trading - Jammu Links News
Atara Biotherapeutics Inc Azioni (ATRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atara Biotherapeutics Inc Azioni (ATRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
May 16 '25 |
Sale |
6.76 |
2,218 |
15,000 |
37,067 |
| Nguyen AnhCo | President and CEO |
May 16 '25 |
Sale |
6.76 |
3,276 |
22,156 |
70,847 |
3.70%
1.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):